Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

Standard for diagnosis and treatment of primary liver cancer (2022 edition) 中文|English ISSN
1001-5256 (Print) ISSN 2097-3497 (Online) CN 22-1108/R Home About Journal 1.Journal …

Significant improvements in the management of hepatocellular carcinoma (HCC) during the
past three years have urged the timely update of clinical guidelines in China. In brief, aMAP …

Purpose Transarterial chemoembolization (TACE) is the standard of care for patients with
intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and …

Hepatocellular carcinoma (HCC) ranks among the most common cancers worldwide and
remains to be a major global health care problem. Until 2007, no effective therapies were …

Purpose The aim of this retrospective study was to compare the clinical outcomes of
pembrolizumab-lenvatinib-transarterial chemoembolization (TACE) versus lenvatinib-TACE …

Background: The preoperative selection of patients with intermediate-stage hepatocellular
carcinoma (HCC) who are likely to have an objective response to first transarterial …

Local and regional therapies are recommended for patients with hepatocellular carcinoma
(HCC) in very early (Barcelona Clinic Liver Cancer [BCLC] 0), early (BCLC A), and …

The aim of any oncological treatment is not just to eliminate the tumour, but to maximise
patient survival and quality of life. Since the liver has a vital function, any radical treatment …